Metabolism and Target Organ Damage,
Journal Year:
2023,
Volume and Issue:
3(1), P. 1 - 1
Published: Jan. 1, 2023
Liver
fibrosis
is
critical
for
liver-related
outcomes
and
mortality
in
chronic
liver
disease,
irrespective
of
etiology,
including
nonalcoholic
fatty
disease
(NAFLD).
NAFLD
has
been
viewed
as
an
independent
correlate
cardiovascular
risk.
This
review
article
briefly
describes
the
cellular
molecular
pathomechanisms
underlying
hepatic
fibrosis.
We
then
address
noninvasive
assessment
Finally,
we
discuss
published
evidence
supporting
biomarkers’
role
assessing
risk
among
patients
with
NAFLD.
While
histological
diagnostic
standard
fibrosis,
specifically
techniques,
equations
based
on
anthropometric
parameters,
laboratory
indices,
elastometry
obtained
imaging
techniques.
The
former
group
includes
AST:
ALT
ratio,
Forns
Index,
AST-to-platelet
ratio
index
score,
BARD
(BMI,
AAR,
Diabetes)
fibrosis-4
(FIB-4),
gamma-glutamyl
transferase-to-platelet
Hepamet
score.
latter
comprises
elastographic
techniques
associated
ultrasonography
or
magnetic
resonance.
Our
literature
identified
numerous
studies
demonstrating
that
biomarkers
(the
most
common
being
FIB-4)
predict
overall
major
events
patients.
mechanisms
accounting
this
association
are
reviewed.
In
addition
to
at
baseline,
during
follow-up,
after
therapeutic
interventions
patients,
may
these
Obesity Facts,
Journal Year:
2024,
Volume and Issue:
17(4), P. 374 - 444
Published: Jan. 1, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
termed
non-alcoholic
fatty
(NAFLD),
is
defined
as
(SLD)
in
the
presence
of
one
or
more
cardiometabolic
risk
factor(s)
and
absence
harmful
alcohol
intake.
The
spectrum
MASLD
includes
steatosis,
metabolic
steatohepatitis
(MASH,
NASH),
fibrosis,
cirrhosis
MASH-related
hepatocellular
carcinoma
(HCC).
This
joint
EASL-EASD-EASO
guideline
provides
an
update
on
definitions,
prevention,
screening,
diagnosis
treatment
for
MASLD.
Case-finding
strategies
with
using
non-invasive
tests,
should
be
applied
individuals
factors,
abnormal
enzymes,
and/or
radiological
signs
hepatic
particularly
type
2
diabetes
(T2D)
obesity
additional
factor(s).
A
stepwise
approach
blood-based
scores
(such
FIB-4)
and,
sequentially,
imaging
techniques
transient
elastography)
suitable
to
rule-out/in
advanced
which
predictive
liver-related
outcomes.
In
adults
MASLD,
lifestyle
modification
-
including
weight
loss,
dietary
changes,
physical
exercise
discouraging
consumption
well
optimal
management
comorbidities
use
incretin-based
therapies
(e.g.
semaglutide,
tirzepatide)
T2D
obesity,
if
indicated
advised.
Bariatric
surgery
also
option
obesity.
If
locally
approved
dependent
label,
non-cirrhotic
MASH
significant
fibrosis
(stage
≥2)
considered
a
MASH-targeted
resmetirom,
demonstrated
histological
effectiveness
acceptable
safety
tolerability
profile.
No
pharmacotherapy
can
currently
recommended
cirrhotic
stage.
Management
adaptations
drugs,
nutritional
counselling,
surveillance
portal
hypertension
HCC,
transplantation
decompensated
cirrhosis.
Biosensors and Bioelectronics,
Journal Year:
2024,
Volume and Issue:
251, P. 116100 - 116100
Published: Feb. 2, 2024
Invasive
methods
such
as
blood
collection
and
biopsy
are
commonly
used
for
testing
liver
kidney
function,
which
painful,
time-consuming,
require
trained
personnel,
may
not
be
easily
accessible
to
people
their
routine
checkup.
Early
diagnosis
of
diseases
can
prevent
severe
symptoms
better
management
these
patients.
Emerging
approaches
breath
sweat
analysis
have
shown
potential
non-invasive
disease
diagnosis.
Among
the
many
markers,
ammonia
is
often
a
biomarker
monitoring
functions.
In
this
review
we
provide
an
insight
into
production
expulsion
gas
in
human
body,
different
that
could
potentially
use
analytical
devices
chemiresistive
sensors
gas.
The
also
provides
understanding
materials,
doping
agents
substrates
develop
multifunctional
sensors.
Finally,
current
challenges
possible
future
trends
been
discussed.
Diabetes Spectrum,
Journal Year:
2024,
Volume and Issue:
37(1), P. 9 - 19
Published: Feb. 1, 2024
The
prevalence
of
nonalcoholic
fatty
liver
disease
(NAFLD)
in
the
United
States
is
38%,
having
increased
by
50%
within
past
3
decades.
estimated
NAFLD
among
people
with
type
2
diabetes
55–70%.
presence
associated
a
higher
likelihood
progression
to
fibrosis
development,
transplant,
and
death.
Cardiovascular
main
cause
mortality
NAFLD,
risk
death
significantly
both
diabetes.
carries
high
patient
economic
burdens
but
low
awareness
general
public
health
care
providers.
This
article
reviews
epidemiology
discusses
need
for
appropriate
stratification,
referral
specialty
care,
management
cardiometabolic
factors,
treatment
disease.
authors
present
call
action
raise
address
its
increasing
burden
systematic
efficient
manner.
Journal of Hepatology,
Journal Year:
2024,
Volume and Issue:
81(2), P. 345 - 359
Published: March 28, 2024
The
rising
prevalence
of
liver
diseases
related
to
obesity
and
excessive
use
alcohol
is
fuelling
an
increasing
demand
for
accurate
biomarkers
aimed
at
community
screening,
diagnosis
steatohepatitis
significant
fibrosis,
monitoring,
prognostication
prediction
treatment
efficacy.
Breakthroughs
in
omics
methodologies
the
power
bioinformatics
have
created
excellent
opportunity
apply
technological
advances
clinical
needs,
instance
development
precision
personalised
medicine.
Via
technologies,
biological
processes
from
genes
circulating
protein,
as
well
microbiome
-
including
bacteria,
viruses
fungi,
can
be
investigated
on
axis.
However,
there
are
important
barriers
omics-based
biomarker
discovery
validation,
semi-quantitative
measurements
untargeted
platforms,
which
may
exhibit
high
analytical,
inter-
intra-individual
variance.
Standardising
methods
need
validate
them
across
diverse
populations
presents
a
challenge,
partly
due
disease
complexity
dynamic
nature
expression
different
stages.
Lack
validity
causes
lost
opportunities
when
studies
fail
provide
knowledge
needed
regulatory
approvals,
all
contributes
delayed
translation
these
discoveries
into
practice.
While
no
matured
implementation,
extent
data
generated
has
enabled
hypothesis-free
plethora
candidate
that
warrant
further
validation.
To
explore
many
hepatologists
detailed
commonalities
differences
between
various
layers,
both
advantages
approaches.
Journal of Clinical and Translational Hepatology,
Journal Year:
2024,
Volume and Issue:
000(000), P. 000 - 000
Published: Nov. 4, 2024
With
the
rising
epidemic
of
obesity,
metabolic
syndrome,
and
type
2
diabetes
mellitus
in
China,
dysfunction-associated
non-alcoholic
fatty
liver
disease
has
become
most
prevalent
chronic
disease.
This
condition
frequently
occurs
Chinese
patients
with
alcoholic
hepatitis
B.
To
address
impending
public
health
crisis
its
underlying
issues,
Society
Hepatology
Medical
Association
convened
a
panel
clinical
experts
to
revise
update
"Guideline
prevention
treatment
(2018,
China)".
The
new
edition,
titled
for
(Version
2024)",
offers
comprehensive
recommendations
on
key
including
screening
monitoring,
diagnosis
evaluation,
treatment,
follow-up
steatotic
Metabolic
is
now
preferred
English
term
used
interchangeably
Additionally,
guideline
emphasizes
importance
multidisciplinary
collaboration
among
hepatologists
other
specialists
manage
cardiometabolic
disorders
effectively.
Radiology,
Journal Year:
2025,
Volume and Issue:
314(1)
Published: Jan. 1, 2025
Photoacoustic
microscopy
imaging
could
be
used
to
evaluate
the
severity
of
liver
fibrosis
by
means
an
analysis
structural
and
functional
characteristics
lobules.
